Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
Discovery and development of beta-blockers when to use antihypertensive medications and which level of blood pressure to target. A balance has to be found between the potential risk to the health of the baby related to drug-exposure and the risk to the mother and baby due to an untreated medical condition (severe hypertension). Antihypertensive drug use during pregnancy is relatively common and increasing. Only a small proportion of available antihypertensive drugs have been tested in pregnant women, and many are contraindicated. It is important to make the exposure of medications to the baby as small as possible. It is not clear if treating women who